Vedroprevir

N/A

Report date: 2023/01/03 18:04:13
NME

Base Information

Drug NameVedroprevir
Drug Alias NameVDV维卓瑞韦vedroprevirum维曲瑞韦维屈普韦 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingHepatitis C, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesOctapharma
Inactive CompaniesGilead Sciences IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksKEGG